Real-world impact of once-weekly subcutaneous semaglutide after two years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.

People treated with semaglutide in routine clinical practice experienced clinically relevant and sustained improvements in glycaemic control after 180, 360, 540, and 720 days irrespective of former GLP-1RA exposure comparable with effects observed in clinical studies. These results support the use of semaglutide in routine clinical practice for long-term management of T2D. This article is protected by copyright. All rights reserved.